Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 38
Region Latin America at a glance
Diabetes trend in population
Population with diabetes
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
80
Diabetes growth rate
NN Insulin MS
NN OAD MS
bDKK
16
NN GLP-1 MS
First nine months of
2018
Sales
(mDKK)
YTD
growth²
120%
66%
Long-acting insulin³
528
27%
100%
Premix insulin4
92
14%
60
105%
40
68
12
Fast-acting insulin5
246
34%
9.3%¹
80%
Human insulin
577
4%
Insulin
7.8%¹
Total insulin
8
60%
1,443
18%
41
GLP-16
392
29%
40%
20
20
Other diabetes care?
48
38%
4
6.8%¹
20
OAD
20%
Diabetes care
1,883
20%
Obesity (SaxendaⓇ)
277
69%
0
2000
2017
2045
Aug
2013
0%
Biopharm³
876
72%
Aug
2018
Total
3,036
35%
Latin America population 2018: ~0.6 billion people and diabetes
prevalence ~9.3%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share for insulin as of Aug 2018: Sanofi 32%
and Eli Lilly 19%
Competitor value market share for GLP-1 as of Aug 2018: Eli Lilly 30%
and AstraZeneca 1%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Aug, 2018 value figures
2 Percentage change in local currency from YTD Q3 2017 to YTD Q3 2018
3 Comprises Tresiba®, XultophyⓇ and Levemir®; 4 Comprises NovoMixⓇ
and RyzodegⓇ; 5 Comprises NovoRapidⓇ; 6 Comprises VictozaⓇ;
7 Comprises Novo NormⓇ and needles; 8 Comprises primarily
NovoSeven®, Novo Eight® and Norditropin®View entire presentation